drugset / Trial / NCT00004934

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

NCT00004934

RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than paclitaxel and carboplatin alone for ovarian epithelial, fallopian tube, or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and carboplatin with or without epirubicin in treating patients who have stage IIB, stage III, or stage IV invasive ovarian epithelial, fallopian tube, or peritoneal cancer.

Timeline

Start
1999-08
Primary completion
Completion
2003-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule 75 mg/m2 Intravenous
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous